RE
LCTX icon

RBC Europe’s Lineage Cell Therapeutics LCTX Stock Holding History

RBC Europe’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-5,700
Closed -$10K – 1216
2020
Q4 		$10K Hold
5,700
– – ﹤0.01% 877
2020
Q3 		$5.34K Hold
5,700
– – ﹤0.01% 899
2020
Q2 		$4.96K Hold
5,700
– – ﹤0.01% 869
2020
Q1 		$4.72K Hold
5,700
– – ﹤0.01% 835
2019
Q4 		$5.07K Hold
5,700
– – ﹤0.01% 900
2019
Q3 		$5.59K Hold
5,700
– – ﹤0.01% 885
2019
Q2 		$6.27K Hold
5,700
– – ﹤0.01% 885
2019
Q1 		$7.47K Hold
5,700
– – ﹤0.01% 876
2018
Q4 		$5.2K Sell
5,700
-815
-13% -$1.25K ﹤0.01% 919
2018
Q3 		$13.4K Hold
6,515
– – ﹤0.01% 771
2018
Q2 		$11.7K Buy
+6,515
New +$13.1K ﹤0.01% 815

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $319M AUM 12.55% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PGP
Prescott General Partners Boca Raton, Florida $1.96B AUM 58.65% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

RBC Europe's LCTX Position: Q1 2021 in Review

RBC Europe sold out of Lineage Cell Therapeutics (LCTX) in Q1 2021, closing a stake of 5,700 shares — an estimated $10K sold.

RBC Europe first reported a position in LCTX in Q2 2018 and held it in 11 quarters. The position peaked at $13.4K in Q3 2018. 102 funds tracked by Wall St. Rank hold LCTX as of Q1 2021.

  • RBC Europe reported no remaining Lineage Cell Therapeutics position as of Q1 2021 after selling out during the quarter.
  • RBC Europe sold 5,700 Lineage Cell Therapeutics shares in Q1 2021, an estimated $10K.
  • RBC Europe first reported a position in Lineage Cell Therapeutics in Q2 2018 and held it in 11 quarters.
  • RBC Europe's Lineage Cell Therapeutics position peaked at $13.4K in Q3 2018.
  • 102 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q1 2021.

Based on RBC Europe's 13F filing for Q1 2021, filed 9 Nov 2023.